Frederic Ors has been appointed CEO of Immunovaccine Inc, a Halifax-based developer of cancer immunotherapies and infectious diseases vaccines. Bergen was Immunovaccine's chief business officer and was acting CEO for the past month. He heads the firm as it transitions from an R&D-centric firm to one focused on commercialization. Prior to joining the firm, Ors was VP business development & strategic planning at Quebec City-based Medicago, an affiliate of Mitsubishi Pharma. He holds a BSC in biology and a MSc in management of intellectual property projects in biotechnology....